8-K: Moleculin Biotech Nears MIRACLE Trial Data Unblinding

Moleculin Biotech announces imminent unblinding of its pivotal MIRACLE trial data for Annamycin in R/R AML, with preliminary results showing significant outperformance.

Summary

• Moleculin Biotech is approaching the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial, evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML).
• The trial compares two arms of Annamycin plus cytarabine against a control arm of cytarabine plus placebo.
• The first unblinding is expected before June 30, 2026.
• Preliminary blinded efficacy data for the first 45 subjects show a composite complete remission rate (CRc) exceeding 40% and a complete remission (CR) rate of approximately 30%.
• These results represent a significant improvement compared to historical CR rates of 17-18% for cytarabine alone in similar patient populations.
• The median age of enrolled subjects is in the mid-60s, with over 30% having relapsed from or become refractory to a prior venetoclax regimen.
• As of May 1st, 56 subjects have been recruited, with the company on track to recruit the 90th subject in Part A by Q3 2026.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA and EMA for R/R AML, and patent protection through 2040.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive announcement due to the strong preliminary efficacy data showing significant outperformance against the standard of care and the imminent unblinding of further data.

Positives

• Preliminary blinded efficacy data for the first 45 subjects show a CRc exceeding 40% and a CR rate of approximately 30%.
• These CR rates represent a ~67% improvement compared to historical CR rates of 17-18% for cytarabine alone in similar patient populations.
• The trial is on track to recruit the 90th subject in Part A by Q3 2026, with 56 subjects already recruited as of May 1st.
• The company continues to expect the first data unblinding prior to June 30, 2026.
• Annamycin has demonstrated continued absence of cardiotoxicity in preliminary data.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA and EMA for R/R AML.
• Annamycin has composition of matter patent protection through 2040, potentially extending to 2045.

Negatives

• Moleculin will require significant additional financing, for which the Company has no commitments, to conduct its clinical trials.
• The transition from Part A to Part B of the MIRACLE trial may require more time due to the increased data involved in the full 90-subject unblinding.

Risks

• The company requires significant additional financing, for which there are no commitments, to conduct its clinical trials.
• Forward-looking statements are subject to risks and uncertainties, including potential material differences between expectations and actual results.
• The success of Annamycin is dependent on regulatory approvals, which are not guaranteed.
• The company's ability to secure necessary financing on a timely basis is critical for achieving milestones.

Future Outlook

The company expects the first unblinding of data from the MIRACLE trial prior to June 30, 2026. Recruitment of the second group of 45 subjects in Part A is expected to be fully recruited in Q3 2026. Unblinding for the full 90 subjects in Part A may require more time. The company believes it has substantially de-risked the development pathway towards potential approval for Annamycin for AML treatment, subject to future filings and feedback.

Management Comments

• "The data coming from MIRACLE is encouraging," said Walter Klemp, Chairman and CEO of Moleculin.
• "For decades, cytarabine monotherapy regimens, although one of the current standards of care, have set a relatively low bar in relapsed or refractory AML, with historical complete remission rates hovering around 17-18% in previously referenced clinical trials."
• "With our trial comparing two arms of Annamycin in combination with cytarabine compared to cytarabine with a placebo, we are looking forward to the opportunity of showing Annamycin is additive to cytarabine alone in a head to head trial."
• "Against this backdrop, the data emerging from MIRACLE highlight what could be a substantial advancement, suggesting that we may finally be moving beyond the limitations that have defined standard-of-care outcomes."

Industry Context

StockSavvy.ai notes that the positive preliminary results for Annamycin in R/R AML, particularly its potential to overcome resistance mechanisms and lack of cardiotoxicity, position it as a potentially significant advancement in a challenging therapeutic area with high unmet need.

Comparison to Industry Standards

• Historical complete remission (CR) rates for cytarabine alone in similar R/R AML patient populations are approximately 17-18%.
• The preliminary blinded CR rate for the first 45 subjects in the MIRACLE trial approximates 30%, representing a ~67% improvement over the historical standard of care.
• The preliminary blinded composite complete remission rate (CRc) for the first 45 subjects exceeds 40%.

Stakeholder Impact

• Shareholders: Potential positive impact on share price due to promising clinical trial results and de-risking of Annamycin's development pathway, contingent on securing financing.
• Patients: Potential for a new, more effective treatment option for relapsed or refractory AML, with improved remission rates and reduced cardiotoxicity.
• Healthcare Providers: Introduction of a novel therapeutic agent that may offer better outcomes for a challenging patient population.

Next Steps

• Unblinding of data for the first 45 subjects in the MIRACLE trial before June 30, 2026.
• Recruitment of the second group of 45 subjects in Part A of the MIRACLE trial to be completed in Q3 2026.
• Unblinding of data for the second group of 45 subjects in Part A expected in late H2 2026.
• Potential transition from Part A to Part B of the MIRACLE trial.
• Continued development of Annamycin for R/R AML and soft tissue sarcoma.
• Further filings with potential additional feedback from the FDA and foreign equivalents regarding Annamycin approval.

Key Dates

Recommendation

The preliminary data from the MIRACLE trial demonstrate a significant improvement in complete remission rates compared to the current standard of care for relapsed/refractory AML, with a notable absence of cardiotoxicity. The imminent unblinding of further data and the company's progress in patient recruitment suggest a strong potential for Annamycin's approval and market success, despite the acknowledged need for future financing.

Keywords

Annamycin, Moleculin Biotech, MIRACLE Trial, Acute Myeloid Leukemia, AML, Relapsed Refractory AML, Clinical Trial, Oncology